Latest News

ProMIS Neurosciences reported no cases of ARIA-E in a six-month blinded interim analysis of PMN310, an oligomer-selective antibody in the phase 1b PRECISE-AD trial for Alzheimer disease, alongside early biomarker signals consistent with target engagement.

Carrie Hersh, DO, MSc, FAAN, president of the Consortium of Multiple Sclerosis Centers, discussed key sessions presented on disability progression, emerging biomarkers, and the shift toward comprehensive, patient-centered MS care.

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, talked about the need to rethink multiple sclerosis clinical trial design by recognizing immune cells’ potential neuroprotective roles.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, director of the multiple sclerosis research unit at Ottawa Hospital, outlined how research-integrated multiple sclerosis care can refine treatment strategies in clinical practice.

Postmortem analyses of 8 individuals with SOD1-ALS who received tofersen showed widespread drug distribution across somatic motor system tissues and reductions of up to 84% in lumbar spinal cord SOD1 protein levels.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is tau-targeting therapies for Alzheimer disease!

Joey English, MD, Chief Medical Officer of Route 92 Medical, discusses the company's reperfusion platform, the goals of the SUMMIT RISE real-world evidence study, and what vessel-matched catheter technology could mean for acute ischemic stroke care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 24, 2026.

Andrew Lee, MD, PhD, cofounder and CEO of Spot Biosystems, discusses the company's extracellular vesicle platform, the first non-viral delivery of full-length dystrophin in patients with Duchenne muscular dystrophy.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.